Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Qiagen Buys STAT-Dx To Launch Next-Gen Syndromic Testing System

Executive Summary

Qiagen has agreed to acquire STAT-Dx, a start-up that developed a multiplex diagnostic for common syndromes, for about $147m in upfront cash, and up to $44m in regulatory and commercial milestones.

Advertisement

Related Content

Catalan Biotechs Boosted By International Backers
Device/Diagnostics Quarterly Deal-Making Statistics, Q1 2018
M&A Analysis: January, Crisp Start To The Year
STAT-Dx Seals CE-IVD Mark For POC Syndromic Testing System

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT122141

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel